Version history

{
  "session_id": "sess_SDA-2026-04-08-gap-debate-20260406-062033-fecb8755",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "us.anthropic.claude-sonnet-4-20250514-v1:0",
  "action": "support",
  "content": "## **UPDATED FEASIBILITY WITH CLINICAL DATA**\n\n### **TIER 1 TARGETS - IMMEDIATE COMMERCIAL VIABILITY**\n\n#### **1. NAD+ Salvage Pathway (NAMPT/CD38) - HIGHEST PRIORITY**\n\n**Clinical Validation:**\n- **NCT04430517**: McLean Hospital studying NR in MCI/mild AD (n=50, active)\n- **NCT05617508**: Completed Phase 2 dose optimization (n=80, up to 3g daily)\n- **NCT05040321**: Brigham & Women's testing MIB-626 BBB penetration\n- **NCT07278492**: MIB-626 in Down syndrome (Alzheimer's model)\n\n**Competitive Landscape:**\n- **ChromaDex Corp**: NIAGEN® (NR supplement) - $100M+ revenue\n- **Elysium Health**: BASIS (NAD+ precursors) - consumer market\n- **Metro International Biotech**: Clinical-grade NMN development\n- **MetroBiotech**: Advanced NAD+ therapeutics\n\n**Investment Thesis:** \n- Strong clinical precedent with 4+ active trials\n- Proven CNS penetration (MIB-626 data)\n- Multiple chemical approaches (NR, NMN, activators)\n- **Immediate opportunity**: Partner with existing players or develop next-gen formulations\n\n**Timeline/Investment:** 4-7 years, $200-500M (fast-follower strategy)\n\n#### **2. mTOR Pathway Repurposing - STRONG SECOND**\n\n**Clinical Validation:**\n- **NCT04629495**: UT San Antonio Phase 2 rapamycin in MCI/AD (n=40, recruiting)\n- **NCT04200911**: Completed proof-of-concept CNS penetration study\n- **NCT06022068**: Karolinska Institute PET imaging study completed\n\n**Competitive Assessment:**\n- **University of Texas**: Leading academic effort (rapamycin repurposing)\n- **Karolinska Institute**: European clinical development\n- **No major pharma investment yet** - opportunity exists\n\n**Investment Thesis:**\n- FDA-approved drug (de-risked safety profile)\n- Proven CNS activity in ongoing trials\n- Repurposing advantage reduces development costs\n- **Market gap**: No major pharma player committed\n\n**Timeline/Investment:** 5-8 years, $300-600M (repurposing advantage)\n\n### **TIER 2 TARGETS - MEDIUM-TERM OPPORTUNITIES**\n\n#### **3. P2Y12 Modulation - UNDEREXPLORED CNS APPLICATION**\n\n**Clinical Reality Check:**\n- **NCT06714526**: Only CNS-related trial (stroke prevention, not AD)\n- **No AD-specific P2Y12 trials identified**\n- Clopidogrel has extensive cardiovascular safety data\n\n**Competitive Gap:**\n- Virgin territory for neurodegeneration\n- Established safety profile from cardiology use\n- **Need**: CNS-penetrant positive allosteric modulators\n\n**Investment Thesis:**\n- Large unmet medical need\n- Proven target class with known pharmacology\n- Requires novel chemistry for CNS application\n- **Risk**: Bleeding safety concerns may limit dosing\n\n**Timeline/Investment:** 8-12 years, $800M-1.2B (novel chemistry required)\n\n### **TIER 3 TARGETS - HIGH RISK/HIGH REWARD**\n\nThe remaining targets (lipid droplets, mitochondrial contacts, lactate shuttle, sphingolipids) show limited clinical precedent and significant technical challenges.\n\n## **FINAL INVESTMENT RECOMMENDATIONS**\n\n### **IMMEDIATE ACTION (6-24 months):**\n\n1. **License/acquire NAD+ assets** from ChromaDex, Elysium, or MetroBiotech\n2. **Initiate academic collaboration** with UT San Antonio (mTOR) or McLean Hospital (NAD+)\n3. **Conduct market analysis** of APOE4-stratified patient populations\n\n### **MEDIUM-TERM DEVELOPMENT (2-5 years):**\n\n1. **NAD+ Enhancement**: Develop APOE4-specific formulations or delivery systems\n2. **mTOR Modulation**: Create CNS-optimized rapalogs or intermittent dosing protocols\n3. **P2Y12 PAMs**: Initiate medicinal chemistry for brain-penetrant modulators\n\n### **PARTNERSHIP OPPORTUNITIES:**\n\n- **ChromaDex**: NAD+ precursor expertise and market presence\n- **University of Texas**: mTOR repurposing clinical leadership\n- **Alector**: Microglial biology and TREM2 expertise\n- **Denali Therapeutics**: CNS delivery platform technologies\n\n**Bottom Line**: NAD+ salvage pathway offers the fastest path to clinic with existing clinical validation, while mTOR repurposing provides a strong risk-adjusted opportunity. The other hypotheses require substantial additional validation before warranting significant investment.",
  "tokens_used": "1007",
  "persona_id": "persona-domain_expert"
}